HAEMATO PHARM GmbH

HAEMATO PHARM GmbH specializes in the manufacture and sale of generics and EU original medicines. With its product portfolio, the company focuses on five major therapeutic areas: HIV / AIDS, Neurology, Oncology, Rheumatology and Urology.

HAEMATO MED GmbH

HAEMATO MED GmbH is an innovative healthcare company specializing in the development and commercialization of pharmaceutical, medical and medical devices for aesthetic surgery and cosmetic dermatology.

HAEMATO AG

HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of high-end specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market was started. HAEMATO AG assumes that first products will hit the market in the coming year, which has already created the basis for further growth and additional income.

News

We inform you about the current business development of HAEMATO AG and about our investor relations activities.
HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

Berlin, 15.12.2020 – M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company’s share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a capital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.01.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.

read more
HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

Berlin, 15.12.2020 – M1 Kliniken AG and HAEMATO AG today signed a contract for the acqui-sition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contri-bution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company’s share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a ca-pital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.1.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.

read more

HAEMATO AG: Expansion of the board of directors: Strengthening the strategic and operative implementation of the product business in the Haemato Group Schönefeld, 30.11.2020 - The supervisory board of HAEMATO AG has appointed Mr. Patrick Brenske to the board of...

read more

Publications

Get an overview of the current status and development of HAEMATO AG. Here you will find information on the current status of the Group and on developments in recent years.

Contact

Do you have any questions or suggestions? We look forward to hearing from you.

Privacy Policy

HAEMATO AG

HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany

Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag